Your browser doesn't support javascript.
loading
Management of transgenderism.
Spack, Norman P.
  • Spack NP; Endocrine Division, Children's Hospital, 300 Longwood Ave, Boston, MA 02115, USA. norman.spack@childrens.harvard.edu
JAMA ; 309(5): 478-84, 2013 Feb 06.
Article en En | MEDLINE | ID: mdl-23385274
ABSTRACT
Gender identity disorder (transgenderism) is poorly understood from both mechanistic and clinical standpoints. Awareness of the condition appears to be increasing, probably because of greater societal acceptance and available hormonal treatment. Therapeutic options include hormone and surgical treatments but may be limited by insurance coverage because costs are high. For patients seeking male-to-female (MTF) change, hormone treatment includes estrogens, finasteride, spironolactone, and gonadotropin-releasing hormone (GnRH) analogs. Surgical options include feminizing genital and facial surgery, breast augmentation, and various fat transplantations. For patients seeking a female-to-male (FTM) gender change, medical therapy includes testosterone and GnRH analogs and surgical therapy includes mammoplasty and phalloplasty. Medical therapy for both FTM and MTF can be started in early puberty, although long-term effects are not known. All patients considering treatment need counseling and medical monitoring.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos del Desarrollo Sexual / Personas Transgénero / Identidad de Género Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2013 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trastornos del Desarrollo Sexual / Personas Transgénero / Identidad de Género Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Año: 2013 Tipo del documento: Article